PKS Advisory Services LLC Takes $801,000 Position in CVS Health Corporation $CVS

PKS Advisory Services LLC purchased a new position in CVS Health Corporation (NYSE:CVS) during the second quarter, HoldingsChannel reports. The institutional investor purchased 11,949 shares of the pharmacy operator’s stock, valued at approximately $801,000.

A number of other institutional investors and hedge funds also recently modified their holdings of CVS. Cantor Fitzgerald Investment Advisors L.P. raised its position in shares of CVS Health by 1.6% in the 2nd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock worth $28,264,000 after buying an additional 6,615 shares during the period. Brandywine Global Investment Management LLC increased its stake in CVS Health by 20.1% during the first quarter. Brandywine Global Investment Management LLC now owns 3,421,519 shares of the pharmacy operator’s stock worth $231,808,000 after acquiring an additional 572,533 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its stake in shares of CVS Health by 122.5% in the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 565,152 shares of the pharmacy operator’s stock valued at $38,289,000 after purchasing an additional 311,098 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its position in CVS Health by 1.4% during the 1st quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 708,479 shares of the pharmacy operator’s stock worth $47,999,000 after purchasing an additional 9,634 shares in the last quarter. Finally, Holderness Investments Co. purchased a new position in CVS Health in the first quarter valued at approximately $300,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS opened at $76.52 on Thursday. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.62. The company has a market cap of $97.13 billion, a P/E ratio of 201.36, a PEG ratio of 0.87 and a beta of 0.60. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $85.15. The stock has a fifty day moving average price of $78.03 and a 200 day moving average price of $70.14.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping the consensus estimate of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to analyst estimates of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, October 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s payout ratio is currently 700.00%.

Analysts Set New Price Targets

Several research firms have recently issued reports on CVS. Wall Street Zen lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. UBS Group upped their price target on shares of CVS Health from $79.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, October 24th. Wells Fargo & Company cut their price objective on CVS Health from $103.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 13th. Royal Bank Of Canada upped their target price on CVS Health from $81.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, Zacks Research downgraded CVS Health from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.41.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.